Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
Poland Prescription To Otc Switch Europe

Poland Kick Starts 2019 With Three Rx-To-OTC Switches

  • News

Executive Summary

Clotrimazole, pyrantel, and ciclopirox olamine have been switched from prescription-to-OTC status by Poland's national drug regulator.

You may also be interested in...



GSK Consumer Separation On Track For Summer '22

COVID-19 has not held back GSK's preparations to create the world's largest standalone consumer health business, with CEO Emma Walmsley confirming separation is on track for summer next year.

People On The Move: Appointments At Sanofi, Enzymatica And Bayer

Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.

Top 10 UK OTC Marketing Stories 2020: Digital Health And Probiotics Lead The Way

HBW Insight's countdown of the top-10 most read UK OTC marketing stories in 2020 includes launches and campaigns from consumer health players such as Sanofi, J&J, GSK and Bayer, amongst others.

Table

View full table

Topics

Related Companies

Tags:
Poland Prescription To Otc Switch Europe
UsernamePublicRestriction

Register

OM004674

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By